Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9468238 | 0.96 | ADRB2 (0.65) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL9764442 | 0.86 | ADRB2 (0.53) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL9764714 | 0.86 | ADRB2 (0.53) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL11882828 | 0.86 | ADRB2 (0.69) | ADRB2ADRB3ADRB1LMNATSHR | |
| Hydrochloric Acid SCHEMBL9764518 | 0.85 | ADRB2 (0.52) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL30869024 | 0.83 | ADRB2 (0.78) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL9468361 | 0.81 | ADRB2 (0.65) | ADRB2ADRB3ADRB1LMNATSHR | |
| SCHEMBL10507768 | 0.81 | ADRB3 (0.69) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL9468370 | 0.80 | ADRB3 (0.68) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL10717538 | 0.79 | KDM4E (0.90) | ADRB2KDM4EGAASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4506734-A1 | METHOD FOR ANALYZING A SOLID-STATE NUCLEAR TRACK DETECTOR | Marvel Fusion GmbH (DE) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024052702-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK1G1, CSNK2A3 | ADRB2 656/4885KDM4E 754/4885GAA 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.